Department of Infectious Diseases, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Department of Nephrology and Hypertension, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Transplantation. 2022 Sep 1;106(9):1875-1883. doi: 10.1097/TP.0000000000004109. Epub 2022 Apr 1.
ABO-incompatible (ABOi) kidney transplantation (KT) expands the kidney donor pool and may help to overcome organ shortage. Nonetheless, concerns about infectious complications associated with ABOi-KT have been raised.
In a nationwide cohort (Swiss Transplant Cohort Study), we compared the risk for infectious complications among ABOi and ABO-compatible (ABOc) renal transplant recipients. Infections needed to fulfill rigorous, prespecified criteria to be classified as clinically relevant. Unadjusted and adjusted competing risk regression models were used to compare the time to the first clinically relevant infection among ABOi-KT and ABOc-KT recipients. Inverse probability weighted generalized mixed-effects Poisson regression was used to estimate incidence rate ratios for infection.
We included 757 living-donor KT recipients (639 ABOc; 118 ABOi) and identified 717 infection episodes. The spectrum of causative pathogens and the anatomical sites affected by infections were similar between ABOi-KT and ABOc-KT recipients. There was no significant difference in time to first posttransplant infection between ABOi-KT and ABOc-KT recipients (subhazard ratio, 1.24; 95% confidence interval [CI], 0.93-1.66; P = 0.142). At 1 y, the crude infection rate was 1.11 (95% CI, 0.93-1.33) episodes per patient-year for ABOi patients and 0.94 (95% CI, 0.86-1.01) for ABOc-KT recipients. Inverse probability weighted infection rates were similar between groups (adjusted incidence rate ratio, 1.12; 95% CI, 0.83-1.52; P = 0.461).
The burden of infections during the first year posttransplant was high but not relevantly different in ABOi-KT and ABOc-KT recipients. Our results highlight that concerns regarding infectious complications should not affect the implementation of ABOi-KT programs.
ABO 不相容(ABOi)肾移植(KT)扩大了肾脏供体库,可能有助于克服器官短缺。然而,人们对 ABOi-KT 相关感染并发症的担忧已经出现。
在一项全国性队列研究(瑞士移植队列研究)中,我们比较了 ABOi 和 ABO 相容(ABOc)肾移植受者感染并发症的风险。需要满足严格的、预先规定的标准才能将感染归类为临床相关。使用未调整和调整后的竞争风险回归模型比较 ABOi-KT 和 ABOc-KT 受者中首次发生临床相关感染的时间。使用逆概率加权广义混合效应泊松回归估计感染的发病率比。
我们纳入了 757 例活体供肾 KT 受者(639 例 ABOc;118 例 ABOi),并确定了 717 例感染事件。ABOi-KT 和 ABOc-KT 受者的病原体谱和感染受累的解剖部位相似。ABOi-KT 和 ABOc-KT 受者之间首次移植后感染的时间无显著差异(亚危险比,1.24;95%置信区间[CI],0.93-1.66;P=0.142)。在 1 年时,ABOi 患者的未调整感染率为 1.11(95%CI,0.93-1.33)/患者年,ABOc-KT 受者为 0.94(95%CI,0.86-1.01)。两组间的逆概率加权感染率相似(调整发病率比,1.12;95%CI,0.83-1.52;P=0.461)。
移植后第一年的感染负担很高,但 ABOi-KT 和 ABOc-KT 受者之间并无明显差异。我们的结果强调,对感染并发症的担忧不应影响 ABOi-KT 计划的实施。